Jesse M. Weiss

Specialty / focus. Jesse M. Weiss is a litigation partner at Cravath, Swaine & Moore (New York), but he is an antitrust litigator, not a patent specialist in his core practice. Cravath, Chambers, Lawdragon, and Super Lawyers profiles all describe his practice as antitrust litigation, regulatory work, and antitrust counseling, with representative matters spanning pharmaceuticals, biotechnology, technology platforms, payments, and consumer/energy markets. His single tracked appearance — as defense-side counsel in Regeneron Pharmaceuticals, Inc. v. Amgen Inc. — fits that pattern: it is the high-stakes antitrust (bundled-rebate) litigation between the two biopharma companies rather than a patent case, although the publicly reported trial team for Amgen in that Delaware action was Gibson Dunn/Young Conaway, so his role appears to have been within Cravath's broader Amgen engagement. I found no reliable evidence of a stand-alone patent docket or IP-specific practice description.

Side preference. Defendant-side only on tracked data (1 defendant appearance, 0 plaintiff). That is consistent with his web-searchable record: he defends large operating companies (Live Nation, Amex, Tesla, Amgen, Corteva, Illumina, Elsevier, Louis Dreyfus) in government and private antitrust matters. No NPE/PAE work is identifiable.

Firm context. Entire career at Cravath — joined as an associate in 2008, elected partner in 2023. No prior firms, no in-house role identified.

Notable cases/outcomes. Tracked matter: Regeneron v. Amgen (D. Del.), in which the defendant Amgen faced a May 2025 jury verdict of $406.8 million (compensatory plus punitive) on Regeneron's PCSK9 inhibitor bundled-rebate claims; Amgen has moved for JMOL/a new trial, so the outcome is not final. Separately, Weiss was part of the Cravath team defending Amgen against the FTC's challenge to its $27.8 billion acquisition of Horizon Therapeutics, which ended in a consent order clearing the deal (recognized as Am Law Litigation Daily's "Litigators of the Week"). He also worked on the successful defense of the FTC's challenge to Illumina's GRAIL acquisition before the FTC's ALJ and the Amex merchant-rules litigation that reached the Supreme Court. Public sources do not tie him to patent verdicts or Federal Circuit appeals.

PTAB/IPR. None identified; no indication of regular IPR/PGR practice.

Bar/education. New York bar (2009); B.A. University of Maryland (2003); J.D. Georgetown University Law Center (2008), magna cum laude.

Caveat: Nearly all web-searchable material concerns his antitrust practice; patent-litigation-specific credentials (if any) are not documented in accessible sources, and multiple lawyers named Jesse Weiss exist, so the disambiguation above relies on the Cravath Georgetown-educated profile matching the tracked case data.